Last reviewed · How we verify
standard treatment in HIV positive
standard treatment in HIV positive is a Nucleoside reverse transcriptase inhibitor Small molecule drug developed by University of Guadalajara. It is currently in Phase 3 development for Treatment of HIV-1 infection in combination with other antiretroviral agents. Also known as: plus Zoledronic Acid 4 mg.
This drug works by inhibiting the replication of the HIV virus.
This drug works by inhibiting the replication of the HIV virus. Used for Treatment of HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | standard treatment in HIV positive |
|---|---|
| Also known as | plus Zoledronic Acid 4 mg |
| Sponsor | University of Guadalajara |
| Drug class | Nucleoside reverse transcriptase inhibitor |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It does this by targeting the viral reverse transcriptase enzyme, preventing the virus from converting its genetic material into DNA that can be integrated into the host cell's genome.
Approved indications
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis (NA)
- Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women (NA)
- Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial (NA)
- Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants
- Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention to Locate Undiagnosed Cases and Reduce HIV-related Stigma (NA)
- Efficacy of EMDR Therapy, as Compared to Treatment as Usual, in Reducing Clinical Symptoms in People With HIV (NA)
- Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard treatment in HIV positive CI brief — competitive landscape report
- standard treatment in HIV positive updates RSS · CI watch RSS
- University of Guadalajara portfolio CI
Frequently asked questions about standard treatment in HIV positive
What is standard treatment in HIV positive?
How does standard treatment in HIV positive work?
What is standard treatment in HIV positive used for?
Who makes standard treatment in HIV positive?
Is standard treatment in HIV positive also known as anything else?
What drug class is standard treatment in HIV positive in?
What development phase is standard treatment in HIV positive in?
What are the side effects of standard treatment in HIV positive?
What does standard treatment in HIV positive target?
Related
- Drug class: All Nucleoside reverse transcriptase inhibitor drugs
- Target: All drugs targeting HIV-1 reverse transcriptase
- Manufacturer: University of Guadalajara — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of HIV-1 infection in combination with other antiretroviral agents
- Also known as: plus Zoledronic Acid 4 mg
- Compare: standard treatment in HIV positive vs similar drugs
- Pricing: standard treatment in HIV positive cost, discount & access